Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 4 675 JPY -1.08%
Market Cap: 358.9B JPY
Have any thoughts about
Tsumura & Co?
Write Note

Tsumura & Co
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tsumura & Co
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Tsumura & Co
TSE:4540
Cash & Cash Equivalents
ÂĄ82.4B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
14%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash & Cash Equivalents
ÂĄ859B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Cash & Cash Equivalents
ÂĄ707.7B
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Cash & Cash Equivalents
ÂĄ515.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash & Cash Equivalents
ÂĄ462.9B
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
16%
Astellas Pharma Inc
TSE:4503
Cash & Cash Equivalents
ÂĄ293B
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
No Stocks Found

Tsumura & Co
Glance View

Market Cap
355B JPY
Industry
Pharmaceuticals

Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.

Intrinsic Value
5 663.28 JPY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Tsumura & Co's Cash & Cash Equivalents?
Cash & Cash Equivalents
82.4B JPY

Based on the financial report for Sep 30, 2024, Tsumura & Co's Cash & Cash Equivalents amounts to 82.4B JPY.

What is Tsumura & Co's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%

Over the last year, the Cash & Cash Equivalents growth was 1%. The average annual Cash & Cash Equivalents growth rates for Tsumura & Co have been 7% over the past three years , 4% over the past five years , and 14% over the past ten years .

Back to Top